Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Upstream Bio, Inc.NASDAQ: UPB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 95.3%

Gross margin was 95.3% in Q1 FY2026, down 4.7 pp from a year earlier. On a trailing-twelve-month basis it was 98.5%, down 1.5 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
95.3%-4.7 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
98.5%-1.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.7 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How UPB compares with its peers on the latest reported figures

  • UPB's LTM Mar 2026 gross margin of 98.5% is the 2nd highest of the 8 companies compared; the peer median is 84.6%.
  • Its year-over-year change of -1.5 pp is the 5th highest of 7, against a peer median of +124.0 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +20.6 pp.
UPB Competitors Peer median
Gross Margin for UPB and competitors
Company Period LTM level YoY 3-year change
ZBIOZenas BioPharma, Inc.FY2025100.0% +2782.8 pp—
UPBUpstream Bio, Inc.LTM Mar 202698.5% -1.5 pp+0.0 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202698.0% -0.0 pp—
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
NVAXNovavax, Inc.LTM Mar 202684.6% -2.8 pp+50.1 pp
SYRESpyre Therapeutics, Inc.LTM Sep 202650.0% ——
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-566.6% +1757.0 pp+17573.1 pp
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
PHVSPharvaris N.V.FY2025— ——
Peer median (excluding UPB) 84.6%+124.0 pp+20.6 pp

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.